Oncobiologics Inc (ONS) CEO Pankaj Mohan Sells 104,131 Shares

Oncobiologics Inc (NASDAQ:ONS) CEO Pankaj Mohan sold 104,131 shares of Oncobiologics stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $1.15, for a total transaction of $119,750.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Oncobiologics Inc (NASDAQ ONS) traded down $0.02 during trading hours on Thursday, reaching $1.16. 29,272 shares of the company were exchanged, compared to its average volume of 110,578. The company has a current ratio of 0.03, a quick ratio of 0.03 and a debt-to-equity ratio of -0.01. Oncobiologics Inc has a fifty-two week low of $0.78 and a fifty-two week high of $3.95.

An institutional investor recently raised its position in Oncobiologics stock. Sabby Management LLC raised its stake in Oncobiologics Inc (NASDAQ:ONS) by 5.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,365,763 shares of the company’s stock after buying an additional 127,293 shares during the period. Sabby Management LLC owned 9.59% of Oncobiologics worth $2,371,000 at the end of the most recent quarter. 18.52% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/21/oncobiologics-inc-ons-ceo-pankaj-mohan-sells-104131-shares.html.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

What are top analysts saying about Oncobiologics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oncobiologics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit